| Dr Curtis Troy Thompson, MD | |
|
9750 Sw Nimbus Ave, Beaverton, OR 97008-7172 | |
| (503) 906-7300 | |
| (503) 245-8219 |
| Full Name | Dr Curtis Troy Thompson |
|---|---|
| Gender | Male |
| Speciality | Pathology - Dermatopathology |
| Location | 9750 Sw Nimbus Ave, Beaverton, Oregon |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457408601 | NPI | - | NPPES |
| 274962 | Medicaid | OR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZD0900X | Pathology - Dermatopathology | 23731 (Oregon) | Primary |
| Entity Name | Curtis Thompson Md & Associates Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861533481 PECOS PAC ID: 8921033945 Enrollment ID: O20050928001130 |
News Archive
Following a kick-off meeting, the TransLUMINAL-B project, which is being led by Charité - Universitätsmedizin Berlin, is now officially underway. Over the next three years, researchers involved in the project will study the process of metastasis formation and the role of malignant cells, which accumulate in the blood and bone marrow of patients with certain types of breast cancer.
A University of Colorado Cancer Center study published online ahead of print in the journal Molecular Cancer Research shows that ALK and ROS1 gene rearrangements known to drive subsets of lung cancer are also present in some colorectal cancers. These results imply that drugs used to target ALK and ROS1 in lung cancer may also have applications in this subset of colorectal cancer patients.
Janssen-Cilag International NV announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending the granting of a marketing authorisation for IMBRUVICA (ibrutinib) in the European Union.
Patients with the most acute type of thrombosis in the leg - known as an arterial thrombosis - risk developing diseases that are far worse than the blood clot itself. The risk of developing cancer during the first six months after the blood clot is three times greater than normal.
Something as seemingly harmless as a heartburn pill could lead cancer patients to take a turn for the worse.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Curtis Troy Thompson, MD Po Box 230457, Tigard, OR 97281-0457 Ph: (503) 906-7300 | Dr Curtis Troy Thompson, MD 9750 Sw Nimbus Ave, Beaverton, OR 97008-7172 Ph: (503) 906-7300 |
News Archive
Following a kick-off meeting, the TransLUMINAL-B project, which is being led by Charité - Universitätsmedizin Berlin, is now officially underway. Over the next three years, researchers involved in the project will study the process of metastasis formation and the role of malignant cells, which accumulate in the blood and bone marrow of patients with certain types of breast cancer.
A University of Colorado Cancer Center study published online ahead of print in the journal Molecular Cancer Research shows that ALK and ROS1 gene rearrangements known to drive subsets of lung cancer are also present in some colorectal cancers. These results imply that drugs used to target ALK and ROS1 in lung cancer may also have applications in this subset of colorectal cancer patients.
Janssen-Cilag International NV announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending the granting of a marketing authorisation for IMBRUVICA (ibrutinib) in the European Union.
Patients with the most acute type of thrombosis in the leg - known as an arterial thrombosis - risk developing diseases that are far worse than the blood clot itself. The risk of developing cancer during the first six months after the blood clot is three times greater than normal.
Something as seemingly harmless as a heartburn pill could lead cancer patients to take a turn for the worse.
› Verified 1 days ago
Jessica A Spies, MD Pathology Medicare: Medicare Enrolled Practice Location: 9750 Sw Nimbus Ave, Beaverton, OR 97008 Phone: 503-906-7300 Fax: 503-245-8219 |